These Analysts Lower Their Forecasts On Zimmer Biomet After Q1 Results

Core Insights - Zimmer Biomet Holdings, Inc. reported better-than-expected earnings for Q1, with adjusted EPS of $1.81, down from $1.94 a year ago, surpassing Street estimates of $1.77 [1] - The company achieved sales of $1.91 billion, reflecting a 1.1% increase on a reported basis and a 2.3% increase on a constant currency basis, nearly aligning with the consensus of $1.9 billion [1] Financial Guidance - For fiscal year 2025, the company expects adjusted EPS in the range of $7.90-$8.10, a decrease from the previous guidance of $8.15-$8.35, compared to consensus expectations of $8.19 [2] - Revenue growth for 2025 is projected at 5.7% – 8.2%, an increase from the earlier expectation of 1% – 3.5%, with a foreign currency exchange impact anticipated between 0.0% and 0.5% [3] Stock Performance and Analyst Ratings - Following the earnings announcement, Zimmer Biomet shares increased by 0.7%, trading at $91.08 [3] - Analysts have adjusted their price targets for Zimmer Biomet, with Baird lowering it from $130 to $115, Wells Fargo from $113 to $98, JP Morgan from $128 to $105, and others making similar reductions [8]